$71.78
-1.97-2.67%
Last update: Nov 10, 7:04 PM
Monopar Therapeutics Inc
MNPRNASDAQ
Monopar Therapeutics fell 11.2% from $83.08 to $73.75, behind the S&P 500's +10.0%. Its worst day was Feb 4 (−11.2%), and its low came Apr 29 at $50.12.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.48 missed the $-0.42 estimate on $0.00 revenue.
+5.4% · S&P 500 −1.7%
Monopar Therapeutics shares rose 10.3%, while the S&P 500 rose 1.0%.
Story events cover the past 12 months · Times ET
+10.3% · S&P 500 +1.0%
Monopar Therapeutics shares fell 10.4%, while the S&P 500 rose 0.1%.
−10.4% · S&P 500 +0.1%
Monopar Therapeutics shares fell 11.2%, while the S&P 500 fell 0.5%.
−11.2%, the year's worst day · S&P 500 −0.5%
EPS of $-0.61 missed the $-0.54 estimate on $0.00 revenue.
−0.8% · S&P 500 −1.7%
Monopar Therapeutics closed at its lowest level of the year, 39.7% below where the year started.
−8.0% · S&P 500 0.0%
EPS of $-0.46 beat the $-0.93 estimate on $0.00 revenue.
−0.7% · S&P 500 +0.8%
Monopar Therapeutics shares rose 19.1%, while the S&P 500 fell 1.5%.
+19.1%, the year's best day · S&P 500 −1.5%
EPS of $-0.62 beat the $-0.65 estimate on $0.00 revenue.
+0.4% · S&P 500 +0.3%
Monopar Therapeutics shares fell 10.5%, while the S&P 500 fell 0.8%.
−10.5% · S&P 500 −0.8%
Where it ended: a close of $73.75 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.85).
Nothing in the past 12 months.
All MNPR dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MNPR and SPY from Benzinga historical bars. Not investment advice.
